Molecular quality controls help to monitor the performance of testing procedures. These tests are helpful to achieve critical and accurate diagnostic information. These controls are used to determine transmissible and genetic diseases too. Moreover, the molecular quality controls also help to monitor the performance of nucleic acid testing protocols for healthcare associated infections, viral load assays and sexually transmitted infections.
Strategic insights for the North America Molecular Quality Controls provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 75.79 Million |
Market Size by 2028 | US$ 155.61 Million |
Global CAGR (2021 - 2028) | 10.8% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Product
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
The geographic scope of the North America Molecular Quality Controls refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The North America molecular quality controls market is expected to reach US$ 155.61 million by 2028 from US$ 75.79 million in 2021; it is estimated to grow at a CAGR of 10.8% from 2021 to 2028. Factors such as growing funds for genomics, declining cost of sequencing procedures, and increasing prevalence of genetic diseases fuel the growth of the market. However, the dearth of skilled professionals hinders the market growth.
Molecular quality controls are used to detect genetic diseases as these aid in the interpretation of results. Downs Syndrome is a genetic disorder that causes due to abnormal cell division, which results in an extra full or partial copy of chromosome 21. As per the US Centers for Disease Control and Prevention (CDC), every year, around 6,000 newborns in the US suffer from the Down syndrome. As a result, prenatal testing for Down syndrome is increasing in the country. Also, growing awareness of breast cancer increases the adoption of genetic testing for hereditary breast cancer. Further, as per CDC, sickle cell disease (SCD) is a common genetic blood disorder in the US that affects ~70,000 to 100,000 Americans. Thus, the increasing prevalence of such genetic diseases propels the demand for molecular quality controls. Genome sequencing has now become one of the common techniques in clinical practices. The growing implementation of genomic sequencing in healthcare systems is supported by substantial government investments, totaling over US$ 4 billion by at least 14 countries. Such continuous funding by the manufacturers and governments in the field of genomics is supporting the growth of the molecular quality controls market.
The outbreak of the COVID-19 pandemic situation shown some favorable scenario for players operating in the molecular quality controls market. The infection of corona among older people has resulted in severe complications and has accounted for a good number of deaths in the country. But during the pandemic situation, life science companies are engaged in development of novel drugs for the treatment of life threaten diseases. Therefore, molecular quality controls are required in drug design & development as well as COVID-19 diagnosis. In April 2020, Thermo Fisher Scientific launched AcroMetrix Coronavirus 2019 (COVID-19) RNA Control to monitor and validate COVID-19 molecular diagnostic tests. Thus, rising numbers of product launches support the growth of the market and has positive impact on the molecular quality controls market.
The North America molecular quality controls market, by product, is segmented into independent controls and instrument specific controls. The independent controls segment held the largest share of the market in 2020 whereas the same is anticipated to register the highest CAGR in the market during the forecast period.
Based on analyte type, the North America molecular quality controls market has been segmented into single analyte controls and multi-analyte controls. The single analyte controls segment held the largest share of the market in 2020, whereas the multi-analyte control segment is estimated to register the highest CAGR in the market during the forecast period.
The North America molecular quality control market, by application, is segmented into, infectious diseases, oncology, genetic testing and other applications. The infectious diseases segment held the largest share of the market in 2020, and the oncology segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on end user, the North America molecular quality control market is segmented into clinical laboratories, hospitals, IVD manufacturers & contract research organizations, academic & research institutes, and other end users. The clinical laboratories segment held the largest share of the market in 2020 and is estimated to register the highest CAGR in the market during the forecast period.
A few of the primary and secondary sources associated with this report on the North America molecular quality control market are the Centers for Disease Control and Prevention (CDC), Council of Scientific & Industrial Research (CSIR), and National Institutes of Health (NIH).
The North America Molecular Quality Controls Market is valued at US$ 75.79 Million in 2021, it is projected to reach US$ 155.61 Million by 2028.
As per our report North America Molecular Quality Controls Market, the market size is valued at US$ 75.79 Million in 2021, projecting it to reach US$ 155.61 Million by 2028. This translates to a CAGR of approximately 10.8% during the forecast period.
The North America Molecular Quality Controls Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Molecular Quality Controls Market report:
The North America Molecular Quality Controls Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Molecular Quality Controls Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Molecular Quality Controls Market value chain can benefit from the information contained in a comprehensive market report.